期刊文献+

噻托溴铵联合小剂量茶碱治疗慢性阻塞性肺疾病的疗效 被引量:2

下载PDF
导出
摘要 目的观察联合使用噻托溴铵及小剂量茶碱对稳定期中重度慢性阻塞性肺疾病(COPO)患者的疗效,为临床选择治疗方案提供参考依据。方法将92例稳定期中重度COPD患者随机分成5组:A组为噻托溴铵组(n=52),B组为噻托溴铵联合小剂量茶碱组(n=29),C组为茶碱组(n=30。A组单独吸八噻托溴铵18阻g/d;C组单独服用茶碱缓释片,100mg/次,早餐前和睡前各1次;8组同时使用噻托溴铵及茶碱缓释片。疗程为6个月。治疗前后分别检测:(1)肺功能;(2)运动耐力:6min行走距离;(5)生活质量:圣乔治呼吸问卷评分;(4)急性发作次数。结果A组及8组FEV.、FEV,/FVC和FEV./预计值,运动耐力及生活质量较用药前均明显升高,且B组急性加重人次较用药前明显减少,与其他两组比较差异有统计学意义(P〈0.05)。而A组用药前后COPD急性发作次数差异无统计学意义(P〉0.05)。C组EFEVI、FEV,/FVC和FEVi/预计值,运动耐力,生活质量及COPD急性发作次数用药前后差异均无统计学意义(P〉0.05)。结论噻托溴铵联合小剂量茶碱能改善稳定期中重度COPD患者肺功能,提高运动耐力,改善生活质量,减少急性发作的次数。 Objective To evaluate the efficacy of the combination of Tiotropium Bromide and small doses of theophylline in the treatment of stable moderate to severe COPD. Methods 92 patients with stable moderate to severe COPD were divided into three groups. In group A,Tiotropium Bromide was used,the combination of Tiotropium Bromide and small doses of theophylline was used in group B,theophylline was used ingroup C,the duration was 6 months. Pulmonary function,exercise capacity quality of life and acute exerbation frequency were evaluated. Results FEV. FEV, FVC/ FEV, exercise capacity quality of life were improved in group A and B,acute exerbation frequency decreased significantly in group B than that in group A and C. Conclusion The combination of Tiotropium Bromide and small doses of theophylline is effective in the treatment of COPD.
出处 《中国农村卫生》 2013年第02Z期115-116,共2页
关键词 慢性阻塞性肺疾病 噻托溴铵 小剂量茶碱 COPD,Tiotropium Bromide,small doses of theophylline
  • 相关文献

参考文献11

  • 1PAUWE L S Pu A,BUIST A S,CALVERi.EY P M,et al.GIobal strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease.NHL BL/WHO Global Initiative for Chronic Obstructive Lung Disease(GOLD)WT0rks hop summary [J].Am J P~espir Crit Care Med,2006,163(5):1256-1276.
  • 2刘升明,王小平,王大礼,周玉民,吕嘉春,郑劲平,钟南山,冉丕鑫.广东部分地区慢性阻塞性肺疾病发病状况调查[J].中华医学杂志,2005,85(11):747-752. 被引量:150
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8235
  • 4P~ABE K F.HURD S,ANZUET0 A.Global strategy for the diag. nosis,management,and prevention of chronic obstructive pulmO- nary disease:GOLD executive summary[J].Am J Respir Crit Cale Med,2007,1 76(6):532-555.
  • 5DISSE B,REIEHL R,SPECK G,et al.B a 679 BR,a novel long- acting antieholinergie bronehodilator[J].Life Sci,2004,52(5/6):537- 544.
  • 6殷凯生,张德平,施毅,孙丽华,闵锐,肖永龙,夏锡荣,谭焰,傅完珍.国产噻托溴铵粉雾剂治疗慢性阻塞性肺疾病的多中心临床研究[J].中华结核和呼吸杂志,2010,33(7):519-523. 被引量:37
  • 7OHTA K,SAWAMOTO S,NAKAJIMA M,et al.The prolonged survival of human eosinophils eith interleukin 5 and its inhibition by theophylline via apoptosis[J].Clin Exp Alletgy,2006,26(Suppl 2):110-115.
  • 8OHTA K,YAMASHITA N.Apoptosis of eosinophils and lympho-eytes in &liergic inflammatioe[J].J Allergy Clin Immunol,2004,104(1):14-21.
  • 9CULP1TT V,DE MATOS C,RUSSEI.L R E,et al.Effect ofthe0-phyHine on induced sputum inflammatory indices and neutmphil chemutaxis in chronic obstructive pulmonary disease[J].Am J Re-spir Crit Care Med,2006,165(10):137l-1376.
  • 10周玉民,王小平,曾祥毅,丘蓉,谢俊芬,刘升明,郑劲平,钟南山,冉丕鑫.茶碱治疗慢性阻塞性肺疾病的随机双盲平行对照研究[J].中华结核和呼吸杂志,2006,29(9):577-582. 被引量:44

二级参考文献53

  • 1王宋平,熊瑛,王鸿程.慢性阻塞性肺疾病的发病机制[J].临床肺科杂志,2005,10(4):521-522. 被引量:45
  • 2有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 3郑劲平,康健,蔡柏蔷,周新,曹兆龙,白春学,钟南山.吸入噻托溴铵干粉与异丙托溴铵定量气雾剂治疗慢性阻塞性肺疾病的疗效与安全性比较[J].中华结核和呼吸杂志,2006,29(6):363-367. 被引量:158
  • 4Zhong N,Wang C,Yao W,et al.Prevalence of chronic obstructive pulmonary disease in China:a large,population-based survey.Am J Respir Crit Care Med,2007,176:753-760.
  • 5Vincken W,van Noord JA,Greefhorst AP,et al.Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.Eur Respir J,2002,19:209-216.
  • 6van Noord JA,Bantje TA,Eland ME,et al.A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease.The Dutch Tiotropium Study Group.Thorax,2000,55:289-294.
  • 7Donohue JF,van Noord JA,Bateman ED,et al.A 6-month,placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.Chest,2002,122:47-55.
  • 8Anzueto A,Tashkin D,Menjoge S,et al.One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium.Puhn Pharmacol Ther,2005,18:75-81.
  • 9García Ruiz AJ,Leiva Fem(a)ndez F,Martos Crespo F.Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol.Arch Bronconeumol,2005,41:242-248.
  • 10O'Donnell DE,Fluge T,Gerken F,et al.Effects of tiotropium on lung hyprinflation,dyspnea and exercise tolerance in COPD.Eur Respir J,2004,23:832-840.

共引文献8410

同被引文献32

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部